Enzymaster, a global biotech company with locations in China, Germany and Singapore specialized in biocatalysis and enzyme engineering, closed a US$7.5M (CNY 50 Mio) Series B-1 funding.
Backers included the Chinese investment firms Weifang Zhongke Haichuang Equity Investment Partnership, Tibet Leimerious Venture Investment Partnership, and Caozhixing Junbo Equity Investment Partnership (which is a re-investment by current shareholder Saisheng Investment).
The company intends to use the funds to strengthen their R&D capacities as well as to broaden their product portfolio and its commercialization.
Enzymaster provides a solution for the development and commercialization of innovative and sustainable enzyme catalysis technologies. With their proprietary BioEngine® Directed Evolution Platform and long-term experience in biocatalysis, the company offers R&D services combined with the establishment of complete technology transfer packages and manufacturing collaborations to fine chemical, pharmaceutical, and other industries. Besides the technology service, Enzymaster also develops and manufactures a portfolio of chemicals based on its proprietary enzymatic tools.